How Has the Fabry Disease Treatment Market Evolved Historically and What is its Current Size?
The fabry disease treatment market has seen considerable growth due to a variety of factors.
• The Fabry disease treatment market has seen strong growth in recent years. It will grow from $2.09 billion in 2024 to $2.28 billion in 2025, with a CAGR of 9.1%.
The growth is attributed to increasing awareness, diagnosis rates, the adoption of enzyme replacement therapies, use of chaperone therapies, investment in rare disease research, and growing healthcare infrastructure.
What Is The Projected Growth Of The Fabry Disease Treatment Template Market?
The fabry disease treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The Fabry disease treatment market is anticipated to grow steadily, reaching $3.2 billion by 2029 with a CAGR of 8.8%.
The expansion is driven by the rising prevalence of the disease, improved awareness and diagnosis, better healthcare infrastructure, increased investment in rare disease research, and broader reimbursement policies. Trends to watch include advances in gene therapy, enzyme replacement therapies, diagnostic techniques, novel treatment methods, and the integration of digital health technologies for patient management.
What Are The Key Drivers Fueling Growth In The Fabry Disease Treatment Market?
The rising prevalence of renal diseases is expected to propel the growth of the Fabry disease treatment market. Kidney diseases, including Fabry disease, are increasing due to factors like genetics and lifestyle choices. Fabry disease, characterized by the buildup of certain substances in the kidneys, necessitates early treatment. The Australian Bureau of Statistics reported that 246,200 people had kidney disease in 2022, showing a 0.2% increase over the past decade, further driving the need for treatments.
What Are The Principal Market Segments In The Global Fabry Disease Treatment Industry?
The fabry disease treatment market covered in this report is segmented –
1) By Treatment: Substrate Reduction Therapy, Enzyme Replacement Therapy, Chaperone Treatment, Other Treatments
2) By Route Of Administration: Oral Route, Intravenous Route
3) By Disease Severity: Classic Fabry Disease, Late-Onset Fabry Disease
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold), Other Substrate Reduction Therapies
2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Other Enzyme Replacement Therapies
3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold)
4) By Other Treatments: Gene Therapy, Symptomatic Treatment
Pre-Book The Fabry Disease Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Fabry Disease Treatment Market?
Companies in the Fabry disease treatment market are developing plant cell-based therapies to improve treatment efficacy and reduce costs. These therapies involve using plant cells to produce enzymes needed by patients with Fabry disease. For example, in May 2023, Chiesi Global Rare Diseases, in collaboration with Protalix BioTherapeutics Inc., received approval for ELFABRIO, an enzyme replacement therapy produced from plant cell cultures that enhances patient convenience by reducing treatment frequency.
Who Are the Key Players In The Fabry Disease Treatment Market?
Major companies operating in the fabry disease treatment market are:
• Sanofi S.A.
• GSK plc
• Takeda Pharmaceutical Company Limited
• CHIESI Farmaceutici S.p.A.
• Ultragenyx Pharmaceutical Inc.
• Amicus Therapeutics Inc.
• JCR Pharmaceuticals Co. Ltd.
• Sangamo Therapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Centogene N.V.
• Protalix BioTherapeutics
• Avrobio Inc.
• ISU Abxis
• Synageva BioPharma Corp.
• Greenovation Biotech GmbH
• CANbridge Pharmaceuticals
• Freeline
• 4D Molecular Therapeutics
• Abeona Therapeutics Inc.
• GC Biopharma Corporation
What Are The Regional Insights Into The Fabry Disease Treatment Market?
North America was the largest region in the fabry disease treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
